Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 121

Results For "CE"

9357 News Found

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules
Drug Approval | November 11, 2024

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension


Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr
News | November 11, 2024

Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr

For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore


Henkel, Covestro and Quad Industries collaborate for advanced medical wearables based on printed electronics
News | November 10, 2024

Henkel, Covestro and Quad Industries collaborate for advanced medical wearables based on printed electronics

Combined capabilities to drive novel healthcare applications presented at MEDICA 2024


Lupin receives tentative approval from USFDA for Raltegravir Tablets
Drug Approval | November 09, 2024

Lupin receives tentative approval from USFDA for Raltegravir Tablets

This product will be manufactured at Lupin’s Nagpur facility in India


K J Somaiya Hospital & Research Centre launches advanced neurosciences centre in Mumbai
News | November 08, 2024

K J Somaiya Hospital & Research Centre launches advanced neurosciences centre in Mumbai

The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients


Emcure Pharmaceuticals posts Q2 FY25 consolidated PAT at Rs. 194.57 Cr
News | November 08, 2024

Emcure Pharmaceuticals posts Q2 FY25 consolidated PAT at Rs. 194.57 Cr

Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024


Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr
News | November 07, 2024

Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr

Revenue growth was fueled by higher volumes and contributions from both existing and new centres


Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
News | November 07, 2024

Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr

US Generics grew 5% to Rs. 467 Crores for the quarter